BiotechTube

MK0524

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Seasonal Allergies

Conditions

Seasonal Allergies

Trial Timeline

Jul 1, 2003 → Oct 1, 2003

NCT ID
NCT00533208

About MK0524

MK0524 is a phase 2 stage product being developed by Merck for Seasonal Allergies. The current trial status is completed. This product is registered under clinical trial identifier NCT00533208. Target conditions include Seasonal Allergies.

What happened to similar drugs?

20 of 20 similar drugs in Seasonal Allergies were approved

Approved (20) Terminated (0) Active (0)
✅montelukastMerckApproved
✅Cell-derived influenza vaccine + Egg-derived influenza vaccineNovartisApproved
✅KetotifenNovartisApproved
✅Fexofenadine HClSanofiApproved
✅Placebo nasal spray + Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ) + Placebo nasal spray + Claritin® SyrupSanofiApproved
✅fexofenadine HClSanofiApproved
✅levocetirizine dihydrochlorideUCBApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00533208Phase 2Completed

Competing Products

20 competing products in Seasonal Allergies

See all competitors
ProductCompanyStageHype Score
mRNA-1273ModernaPhase 1
0
mRNA-1010ModernaPhase 3
0
mRNA-1011.1ModernaPhase 2
0
mRNA-1010ModernaPhase 3
0
mRNA-1010ModernaPhase 3
0
mRNA-1030ModernaPhase 2
0
mRNA-1010ModernaPhase 2
0
mRNA-1010ModernaPhase 3
0
Bilastine + Desloratadine + PlaceboYuhanPhase 3
40
ASP4070 + PlaceboAstellas PharmaPhase 2
35
S-555739 Dose 1 + S-555739 Dose 2 + Cetirizine HCl Dose 1 + S-555739 placebo + Cetirizine HCl placeboShionogiPhase 2
35
Cetirizine + High dose ONO-4053 + Low dose ONO-4053 + PlaceboOno PharmaceuticalPhase 2
35
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + PlaceboSumitomo PharmaPhase 3
40
80 mcg Ciclesonide + 160 mcg Ciclesonide + PlaceboSumitomo PharmaPhase 3
40
Ciclesonide HFA 160 μg + Ciclesonide HFA 80 μg + PlaceboSumitomo PharmaPhase 3
40
GSP 301-1 NS (QD) + GSP 301-2 NS (BID) + GSP 301 Placebo NS + Olopatadine HCl-1 NS (QD) + Olopatadine HCl-2 NS (BID) + Mometasone Furoate-1 NS (QD) + Mometasone Furoate-2 NS (BID)Glenmark PharmaceuticalsPhase 2
35
Molo 1 (also referred as GSP 301-2 NS) + Molo 2 (also referred as GSP 301-1 NS) + Placebo nasal spray + DYMISTA nasal spray + PATANASE nasal sprayGlenmark PharmaceuticalsPhase 2
35
JNJ38224342 + JNJ38224342/placebo + JNJ38224342/placebo + JNJ38224342/placeboJohnson & JohnsonPhase 1
29
Ciclesonide + PlaceboAstraZenecaPhase 3
40
Ciclesonide + PlaceboAstraZenecaPhase 3
40